Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

Won Seog Kim, Yasuhiro Oki, Seok Jin Kim, Sang Eun Yoon, Kirit M. Ardeshna, Yi Lin, Jia Ruan, Pierluigi Porcu, Jonathan E. Brammer, Eric D. Jacobsen, Dok Hyun Yoon, Cheolwon Suh, Felipe Suarez, John Radford, Lihua E. Budde, Jin Seok Kim, Emmanuel Bachy, Hun Ju Lee, Catherine M. Bollard, Arnaud JaccardHye Jin Kang, Shannon Inman, Maryann Murray, Katherin E. Combs, Daniel Y. Lee, Ranjana Advani, Kurt C. Gunter, Cliona M. Rooney, Helen E. Heslop

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


We conducted a phase II clinical trial to develop an autologous EBV-specific T cell product (baltaleucel T) for advanced, relapsed ENKTL. Among 47 patients who provided whole blood starting material for manufacturing the product, 15 patients received a median of 4 doses of baltaleucel T. Thirty-two (68%) patients did not receive baltaleucel-T due to manufacturing failure, rapid disease progression, and death. Of the 15 patients, 10 patients had measurable disease at baseline (salvage cohort), and 5 patients had no disease at baseline assessment (adjuvant cohort). In the 15 patients, the median follow-up duration was 10.2 months (range 2.0–23.5 months), median progression-free survival (PFS) was 3.9 months, and the median overall survival (OS) was not reached. Patients in the salvage cohort achieved a 30% complete response (CR) and a 50% overall response rate (ORR). In the adjuvant cohort, disease progression was reported in three patients and two patients did not relapse during study follow-up. When we compared survival outcomes of seven responders and eight non-responders, the PFS (P = 0.001) and OS (P = 0.014) of responders proved statistically superior to that of non-responders. Baltaleucel-T was well tolerated. We have performed a phase II clinical trial of autologous EBV-specific T cell treatment (baltaleucel-T) in R/R ENKTL. Autologous EBV-specific T cells were well tolerated and demonstrated single-agent activity in R/R ENTKL.

Original languageEnglish (US)
Pages (from-to)2529-2539
Number of pages11
JournalAnnals of Hematology
Issue number10
StatePublished - Oct 2021


  • Epstein-Barr virus
  • Extranodal NK/T-cell lymphoma
  • Immunotherapy
  • Relapsed and refractory
  • Immunotherapy, Adoptive
  • T-Lymphocytes/immunology
  • Herpesvirus 4, Human/immunology
  • Humans
  • Middle Aged
  • Male
  • Treatment Outcome
  • Young Adult
  • Adult
  • Female
  • Aged
  • Epstein-Barr Virus Infections/complications
  • Lymphoma, Extranodal NK-T-Cell/complications

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study'. Together they form a unique fingerprint.

Cite this